Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
NCT ID: NCT00289874
Last Updated: 2022-02-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
421 participants
INTERVENTIONAL
2006-03-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)
NCT00943683
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
NCT00968201
A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)
NCT00140881
Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)
NCT00092144
Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
NCT00337675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
montelukast
montelukast sodium
montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
2
placebo
Comparator: Placebo
Placebo. Up to 3 weeks of treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
montelukast sodium
montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
Comparator: Placebo
Placebo. Up to 3 weeks of treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must demonstrate positive skin prick tests to seasonally relevant geographic aeroallergens
Exclusion Criteria
6 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
References
Explore related publications, articles, or registry entries linked to this study.
Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009 May;46(4):413-20. doi: 10.1080/02770900902847727.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006_001
Identifier Type: -
Identifier Source: secondary_id
0476-336
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.